Macquarie Group’s AEON Biopharma AEON Stock Holding History

Macquarie Group’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13	Closed	-$10	–	1895
2024 Q1	$10	Buy	+13	New	+$9.41K	﹤0.01%	1724

Other funds holding AEON

ACM

Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Macquarie Group's AEON Position: Q2 2024 in Review

Macquarie Group sold out of AEON Biopharma (AEON) in Q2 2024, closing a stake of 13 shares — an estimated $10 sold.

Macquarie Group first reported a position in AEON in Q1 2024 and held it in 1 quarter. The position peaked at $10 in Q1 2024. 24 funds tracked by Wall St. Rank hold AEON as of Q2 2024.

Macquarie Group reported no remaining AEON Biopharma position as of Q2 2024 after selling out during the quarter.
Macquarie Group sold 13 AEON Biopharma shares in Q2 2024, an estimated $10.
Macquarie Group first reported a position in AEON Biopharma in Q1 2024 and held it in 1 quarter.
Macquarie Group's AEON Biopharma position peaked at $10 in Q1 2024.
24 funds tracked by Wall St. Rank held AEON Biopharma as of Q2 2024.

Based on Macquarie Group's 13F filing for Q2 2024, filed 9 Aug 2024.